← all research

Pre-registered 2026-09-09. Cash-flow XBRL NEI/NDI, absent=0 under cash-flow-regime proof, ex-financials, winsorized 1/99, June frozen 12m. Long-only top-10, hold=21, next-open, 10bps, sqrt(252). Split 2016-01-01. Guard PASS.

ArmOOS eligOOS RetOOS SharpeOOS MaxDDTurn/yrCorrMktResidShCorrMomboot-pVerdict
I1 net-issuance79+488.31%0.96-35.08%0.670.92-0.030.690.0010REJECT
I2 financing-composite79+568.04%1.04-33.16%0.890.930.140.700.0006PASS

IS (2010-2015, short) reference

ArmIS RetIS SharpeIS MaxDD
I1 net-issuance+123.23%0.86-17.32%
I2 financing-composite+112.83%0.79-16.41%

Bar (pre-registered): OOS Sharpe >= 0.50 AND bootstrap p < 0.05 AND resid Sharpe vs market > 0. Bonferroni ~= 0.025 for 2 tests noted.

Verdicts (2026-09-09)

  • I1 net-issuance — REJECT (beta). Significant standalone (0.96, p=0.001) with resid -0.03, corrMkt 0.92: the issuance puzzle does not survive long-only on liquid large-caps by itself.
  • I2 financing-composite — PASS (validated) but NOT PROMOTED (no book value). Clears the bar outright (1.04, p=0.0006 — survives Bonferroni — resid +0.14, IS 0.79 consistent, green 10/11 OOS years with only 2022 red at -7.4%): the first fundamental arm with a materially positive residual, i.e. a REAL anomaly replication, not beta. Promotion denied on portfolio grounds, not statistics: 50/50 blend with live EqMom scores 1.267 vs EqMom alone 1.286 (corr 0.70 too high, Sharpe lower) — it would dilute the book it joins. Shelved as a documented diversifier candidate; promotion requires forward shadow evidence or a regime where its -33.2% DD decorrelates. No live change.
  • Program ledger (6 fundamental arms): AG/GP/QMJ-profit/I1 beta-reject, accruals marginal-beta-plus, I2 validated-not-promoted. The EDGAR panel stays as source library; remaining fundamental frontier is issuance-adjacent novelty only (new hypothesis + protocol).